Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  VYNE Therapeutics Inc.    VYNE

VYNE THERAPEUTICS INC.

(VYNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo VYNE Therapeutics Inc.
Vyne Therapeutics Inc., formerly Menlo Therapeutics Inc., is a biopharmaceutical company. The Company is focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions, such as atopic dermatitis, psoriasis and prurigo nodularis. The Company is focused on developing and commercializing a variety of solutions using its Molecule Stabilizing Technology (MST). The Company has a commercial-stage product, AMZEEQ, and several late-stage product candidates. It is also evaluating the use of serlopitant for the treatment of refractory chronic cough. The Company’s serlopitant is a small molecule, highly selective NK1-R antagonist. It is developing serlopitant as a once-daily oral tablet therapy.

Number of employees : 40 people.
Sales per Business
20182019Delta
USD (in Million)%USD (in Million)%
Serlopitant10.64100%---
Sales per region
20182019Delta
USD (in Million)%USD (in Million)%
United States10.64100%---
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 5,93 $
Last Close Price 1,88 $
Spread / Highest target 432%
Spread / Average Target 215%
Spread / Lowest Target 59,6%
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart